GSK plc 6-K, filed Feb 2, 2022
GSK plc (GSK)
6-K
2022-02-02
For: 2022-02-02
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on February 2, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 1 February 2022, London UK
GSK announces settlement between ViiV
Healthcare and Gilead Sciences, Inc. resolving litigation relating
to Biktarvy and ViiV's dolutegravir patents and entry
into a patent licence agreement
● Gilead will make an upfront payment of $1.25
billion to ViiV Healthcare in the first quarter of
2022
● Gilead will also pay a 3% royalty on future US
sales of Biktarvy
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that ViiV
Healthcare, the global specialist HIV company majority-owned by
GSK, with Pfizer Inc. and Shionogi & Co. Limited (Shionogi) as
shareholders, has agreed to settle the global patent infringement
litigation between GSK, Shionogi and Gilead Sciences, Inc. (Gilead)
concerning ViiV Healthcare's patents relating to dolutegravir, an
antiretroviral medication used, together with other medicines, to
treat human immunodeficiency virus (HIV).
ViiV Healthcare, GSK and Shionogi alleged that
Gilead's Biktarvy, a triple combination HIV medicine containing the
HIV integrase inhibitor bictegravir, tenofovir alafenamide and
emtricitabine, infringed certain of their patents relating to
dolutegravir. As a result of the settlement, patent infringement
cases in the US, UK, France, Ireland, Germany, Japan, Korea,
Australia, and Canada will be discontinued.
ViiV Healthcare, GSK, Shionogi and Gilead have entered into a
global settlement agreement and a patent license agreement under
which Gilead has been granted a worldwide licence to certain ViiV
Healthcare patents relating to dolutegravir and a covenant not to
enforce any patents controlled by ViiV Healthcare, GSK or Shionogi
against Gilead in connection with any past or future claims of
infringement relating to Biktarvy. ViiV Healthcare, GSK and Shionogi have also
agreed not to enforce their patents against any future product
containing bictegravir, to the extent that the patent enforcement
relates to the bictegravir component of the
product.
Financial Considerations
Under the terms of the global settlement and licensing agreement,
Gilead will make an upfront payment of $1.25 billion to ViiV
Healthcare which is expected in the first quarter of 2022. In
addition, Gilead will also pay a 3% royalty on all future US sales
of Biktarvy ($6.09 billion in 2020) and in respect of
the bictegravir component of any other future
bictegravir-containing products sold in the US. These royalties
will be payable by Gilead to ViiV Healthcare from 1 February 2022
until the expiry of ViiV Healthcare's U.S. Patent No. 8,129,385 on
5 October 2027. Gilead's obligation to pay royalties does not
extend into any period of regulatory paediatric exclusivity, if
awarded. Regulatory paediatric exclusivity would extend the
period of exclusivity after the expiry of the '385 patent by six
months from 5 October 2027 to 5 April
2028.
The upfront payment and royalty income will be distributed in
proportion to the ordinary shareholding in ViiV Healthcare (GSK
78.3%, Pfizer 11.7%, Shionogi 10%) net of the contingent
consideration liability (CCL) to Shionogi and applicable
tax.
The upfront payment of $1.25 billion will be recorded in GSK's
financial results as an adjusting item in the income statement for
the first quarter of 2022. The future royalty income will be
recorded in total and adjusted results in the income statements for
2022 to 2027 inclusive. Both the settlement and the future royalty
income increase the fair value of the CCL to Shionogi, and the
Pfizer put option.* These increases in fair value will be
reflected in GSK's 2021 full-year and fourth-quarter results, and
the associated charges will be recorded within adjusting
items.
Cash in-flows from the upfront payment and future royalty income
and cash out-flows from the CCL will be recorded in cash generated
from operations. The resulting increased dividends to Shionogi
and Pfizer will be included within financing cashflows. Full
details of the operational accounting of the CCL can be found on
pages 52-53 of GSK's 2020 Annual Report.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in
November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE)
dedicated to delivering advances in treatment and care for people
living with HIV and for people who are at risk of becoming infected
with HIV. Shionogi became a ViiV Healthcare shareholder in October
2012. ViiV Healthcare's aim is to take a deeper and broader
interest in HIV/AIDS than any company has done before and take a
new approach to deliver effective and innovative medicines
for HIV treatment and prevention, as well as support
communities affected by HIV. For more information on the company,
its management, portfolio, pipeline, and commitment, please
visit www.viivhealthcare.com.
Notes
* Under the ViiV Healthcare shareholder agreement, Pfizer has an
option to request an initial public offering, which if not
completed within nine months, will require GSK to acquire Pfizer's
shareholding in ViiV Healthcare.
About GSK
GSK is a science-led global healthcare company. For further
information, please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
|
|
|||
Cautionary
statement regarding forward-looking statements
This
announcement contains statements that are, or may be deemed to be,
"forward-looking statements". GSK cautions investors that any
forward-looking statements or projections made by GSK, including
those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Such factors include, but are not limited to,
those described in the Company's Annual Report on Form 20-F for
2020, GSK's 2021 Q3 Results and any impacts of the COVID-19
pandemic. GSK undertakes no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise. Accordingly, no assurance can be
given that any particular expectation will be met and investors are
cautioned not to place undue reliance on the forward-looking
statements.
This
announcement contains inside information. The person
responsible for arranging the release of this announcement on
behalf of GSK is Victoria Whyte, Company
Secretary.
Registered in England & Wales:
No.
3888792
Registered Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
02, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|